RESEARCH ARTICLE

Prophylactic low-dose, bi-weekly benznidazole treatment fails to prevent *Trypanosoma cruzi* infection in dogs under intense transmission pressure

Juan M. Bustamante[1], Angel M. Padilla[1], Brooke White[1], Lisa D. Auckland[2], Rachel E. Busselman[2], Stephanie Collins[3], Elizabeth L. Malcolm[4], Briana F. Wilson[4], Ashley B. Saunders[4], Sarah A. Hamer[2], Rick L. Tarleton[1]*

1 Center for Tropical and Emerging Global Diseases and Department of Cellular Biology, University of Georgia, Athens, Georgia, United States of America, 2 Department of Veterinary Integrative Biosciences, Texas A&M University, College Station, Texas, United States of America, 3 Chaparral Veterinary Center, Jourdanton, Texas, United States of America, 4 Department of Small Animal Clinical Sciences, College of Veterinary Medicine and Biomedical Sciences, Texas A&M University, College Station, Texas, United States of America

* tarleton@uga.edu

Abstract

Trypanosoma cruzi naturally infects a wide variety of wild and domesticated mammals, in addition to humans. Depending on the infection dose and other factors, the acute infection can be life-threatening, and in all cases, the risk of chagasic heart disease is high in persistently infected hosts. Domestic, working, and semi-feral dogs in the Americas are at significant risk of *T. cruzi* infection and in certain settings in the southern United States, the risk of new infections can exceed 30% per year, even with the use of vector control protocols. In this study, we explored whether intermittent low-dose treatment with the trypanocidal compound benznidazole (BNZ) during the transmission season, could alter the number of new infections in dogs in an area of known, intense transmission pressure. Preliminary studies in mice suggested that twice-weekly administration of BNZ could prevent or truncate infections when parasites were delivered at the mid-point between BNZ doses. Pre-transmission season screening of 126 dogs identified 53 dogs (42.1%) as *T. cruzi* infection positive, based upon blood PCR and Luminex-based serology. Serial monitoring of the 67 uninfected dogs during the high transmission season (May to October) revealed 15 (22.4%) new infections, 6 in the untreated control group and 9 in the group receiving BNZ prophylaxis, indicating no impact of this prophylaxis regimen on the incidence of new infections. Although these studies suggest that rigorously timed and more potent dosing regimen may be needed to achieve an immediate benefit of prophylaxis, additional studies would be needed to determine if drug prophylaxis reduced disease severity despite this failure to prevent new infections.

Author summary

Trypanosoma cruzi, the parasite that causes Chagas disease, circulates extensively in the southern U.S. and working dog populations in south-central Texas are at very high risk of infection, and morbidity and early mortality due to this infection. In this study, we used low level administration of an FDA-approved drug during the transmission season to attempt to prevent new infections in these dogs. Although that effort failed, the study revealed new information about the transmission dynamics and generation of antibody responses and immune control of infection in this high-transmission setting.

Introduction

Chagas disease, caused by the protozoan parasite *Trypanosoma cruzi*, is a problem for human and animal health across the Americas where triatomine vectors are endemic. *T. cruzi* is predominantly transmitted in the feces of infected triatomines through contact with wounds or mucous membranes or ingestion of infected insects or fecal material [1]. Oral transmission is thought to be the most important route in domestic dogs and is a highly efficient mode of transmission [2–5].

Dogs are important to study in the context of Chagas disease for at least three reasons: i) they experience similar disease progression to humans, so are useful to study as a model for human disease especially in considering treatments; ii) they share exposure to vectors with humans in domestic and peridomestic environments and therefore may serve as sentinels for human health risk [6–8]; and iii) canine Chagas disease is an increasingly recognized problem in veterinary medicine, especially in the southern U.S. [9], leading to dog mortality [10].

Large multi-dog kennels in central and south Texas have emerged as settings with particularly high transmission risk, with a recent study documenting incidence of over 30 infections per 100 dogs per year [11], despite variable vector control efforts in and around the kennels. Although some therapeutic regimens have shown promise in reducing disease impact in dogs infected with *T. cruzi* [12], no therapeutics have been evaluated as potential preventatives of *T. cruzi* infection in dogs.

Here we trialed a novel approach for preventing new infections in dogs within multi-dog kennel environments with a history of triatomine occurrence and canine Chagas disease. Disappointingly, prophylaxis during the period of peak adult vector activity [13] with benznidazole (BNZ), an FDA-approved drug used in the treatment of human *T. cruzi* infection, had no impact on the incidence of new infections in this setting, However the long-term impact of prophylaxis on clinical disease was not monitored. Further, this study design provides a model for future evaluation of different prophylactic regimens (higher dose; treatments earlier in the season) in high transmission settings.

Material and methods

Ethics statement

The studies in mice were carried out in strict accordance with the Public Health Service Policy on Humane Care and Use of Laboratory Animals and Association for Assessment and Accreditation of Laboratory Animal Care accreditation guidelines. The protocol was approved by the University of Georgia Institutional Animal Care and Use Committee (AUP #A2021 04-011-Y1-A0). Written informed consent was obtained from dog owners prior to their participation, and this study was approved by the Texas A&M University Institutional

Committee on Animal Use and Care and the Clinical Research Review Committee (IACUC 2018–0460 CA).

Study design

For the studies in mice, female mice, 8–12 weeks old were used for infections throughout the study. Sample sizes were determined based upon our knowledge of heterogeneity in parasite burden during *T. cruzi* infection and published reports using similar experimental strategies. Data collected were included if productive *T. cruzi* infection was established (visualized by luciferase imaging or flow cytometry by detection of *T. cruzi*-tetramer specific CD8+ T cells). The investigators were not blinded during the collection or analysis of data and mice were randomly assigned to treatment groups prior to the start of each experiment.

For studies in dogs, we formed a small network of kennels in central and south Texas with a history of triatomine vector occurrence and canine Chagas disease with owners who were willing to participate in the study. Kennels are identified through (i) canine patients with Chagas disease presenting to the cardiology unit at the TAMU VMTH and (ii) the TAMU Kissing Bug Community Science program, in which many dog owners submit triatomines collected from large kennel environments. At these large kennels, dogs are primarily bred and trained to aid hunting parties. Approximately 40–80 dogs reside within each kennel, and the predominant breeds include Belgian Malinois, Brittany spaniels, English pointers, German shorthaired pointers, Labrador retrievers, and hound dogs. Dogs >3 months of age, including males and females, were eligible for enrollment. Dogs identified after blood screening as seronegative based on multiplex serology and PCR-negative were randomly assigned to treatment groups (S1 Table). At each sampling event, up to 6ml of blood was collected from dogs via jugular venipuncture into clot activator tubes which were shipped on ice overnight to the laboratory after which serum was separated and used for antibody tests, and the clot was used for DNA extractions and PCR testing.

The dog owners/kennel managers gave prophylaxis by placing the encapsulated BNZ in the back of the dog's mouth and encouraging swallowing; in some cases, the capsules were placed into cheese or other food for the dog to consume. Neither the investigators, private veterinarian providing care to the dogs in the field, nor the dog owners were blinded to the treatment groups and no placebo was given to control dogs.

Mice, parasites and infections

C57BL/6J (Stock No:000664) mice (C57BL/6 wild-type) were purchased from The Jackson Laboratory (Bar Harbor, ME) and C57BL/6J-IFN-gamma knockout mice (also known as B6.129S7-Ifngtm1Ts/J; The Jackson Laboratory stock No 002287) were bred in-house at the University of Georgia Animal Facility. All the animals were maintained in the University of Georgia Animal Facility under specific pathogen-free conditions. *T. cruzi* tissue culture trypomastigotes of the Colombiana strain co-expressing firefly luciferase and tdTomato reporter proteins, generated as described previously [14,15], were maintained through passage in Vero cells (American Type Culture Collection (Manassas, VA)) cultured in RPMI 1640 medium with 10% fetal bovine serum at 37°C in an atmosphere of 5% CO_2. Mice were infected intraperitoneally with 10^3 tissue culture trypomastigotes of *T. cruzi*.

Drug treatment and in vivo imaging

Mice were treated with benznidazole twice weekly at a 100mg/kg/day and infected midway during the 3rd week of treatment (Fig 1). Benznidazole (BNZ–Elea Phoenix, Buenos Aires, Argentina) was prepared by pulverization of tablets followed by suspension in an aqueous

Fig 1. **(A)** Schematic representation of prophylactic treatment, infection, and monitoring of mice. WT and IFNγ deficient mice were treated biweekly with 100mg/kg of BNZ over 24 weeks. After the second week of treatment, mice were infected (5–6 animals/group) intraperitoneally with 10^3 trypomastigotes of the Luciferase-expressing Colombiana strain of *T. cruzi*. Control groups of mice were infected and left untreated. **(B)** Representative images showing bioluminescent signal in mice (ventral view) at 14 days post-infection exposure. **(C)** Parasite bioluminescence quantification following D-luciferin injection was measured at the indicated times in the study period. Each data point represents the mean of bioluminescence from 3–6 mice expressed on a logarithmic scale as mean photons/second ±/- standard error of the mean. Grayed box marks the prophylaxis period. * $p<0.03$ relative to both WT groups; ** $p<0.008$ relative to both BNZ-treated groups; *** $p<0.005$ relative to BNZ-treated IFNγ KO group; n.s. bracketed data points are not statistically different. **(D)** Percentage of CD8+ blood lymphocytes specific for the *T. cruzi* TSKb20 epitope (top) and expressing the T cell central memory marker CD127 (bottom) during the study course **(E)** *T. cruzi* DNA determined by quantitative real time polymerase chain reaction in the skeletal muscle, heart, and intestine of untreated and BNZ-treated mice at week 33 of the study (~30 weeks post-infection). Dashed line indicates limit of quantification based on the range of the standard curve.

solution of 1% sodium carboxymethylcellulose with 0.1% Tween 80 and delivered orally by gavage at a concentration dosage of 100mg/kg of body weight. Each mouse received 0.2 ml of this suspension. Luciferase-expressing parasites were quantified in mice by bioluminescent detection. Mice were injected intraperitoneally with D-luciferin (150 mg/kg; PerkinElmer, Waltham, MA) and anesthetized using 2.5% (vol/vol) gaseous isofluorane in oxygen prior to imaging on an IVIS Lumina II imager (Xenogen, Alameda, CA), as previously described [16]. Quantification of bioluminescence and data analysis was performed using Aura Imaging Software version 4.0.7 (Spectral Instruments Imaging, Tucson, AZ).

T-cell phenotyping

Mouse peripheral blood was obtained, processed and analyzed as previously described [15,17]. Whole blood was incubated with a major histocompatibility complex I (MHC I) tetramer containing the *T. cruzi* transialidase TSKB20 peptide (ANYKFTLV/Kb) labeled with BV421 (Tetramer Core Facility at Emory University, Atlanta, GA) and the following labeled antibodies:

anti-CD8 FITC, anti-CD4 APC EF780, anti-CD127 PE (BD Bioscience, San Jose, CA). At least 500,000 cells were acquired using a CyAn ADP flow cytometer (Beckman Coulter, Hialeah, Florida) and analyzed with FlowJo software v10.6.1 (Treestar, Inc., Ashland, OR).

Quantitative polymerase chain reaction

For determination of tissue parasite load in mice, samples of skeletal muscle, heart and intestine were collected at necropsy and processed for quantification of *T. cruzi* DNA by real-time polymerase chain reaction (qPCR) as previously described [15,17,18]. The limit of detection was set at the lowest standard of 0.0017 parasite equivalents per 50 ng of DNA. For detection of *T. cruzi* infection in dogs, DNA was extracted from 250uL of the buffy coat fraction of EDTA-treated blood using the E.Z.N.A Tissue DNA kit (Omega Bio-Tek, Norcross, GA, USA) according to the manufacturer's protocol except 50 μL of elution buffer was used. *T. cruzi*-negative controls (phosphate buffered saline) were included in the DNA extractions. Samples were tested using qPCR for the presence of *T. cruzi* satellite DNA using the Cruzi 1/2 primer set and Cruzi 3 probe in a real-time assay, which amplifies a 166-bp segment of a repetitive nuclear DNA [19,20] as previously described [21] A sample was considered *T. cruzi*-positive if the Ct value was <35 [22].

Multiplex serology

Luminex-based multiplex serological assays were performed as previously described [23,24]. For a number of smaller proteins, fusions of up to 2 individual genes are employed in order to expand the array of antibodies being detected. (TritrypDb.org identifiers: Antigen **1** (Tc1) = fusion of TcBrA4_0116860 and TcYC6_0028190; **2** (Tc2) = fusion of TcBrA4_0088420 and TcBrA4_0101960; **3** (Tc3) = fusion of TcBrA4_0104680 and TcBrA4_0101980; **4** (Tc4) = fusion of TcBrA4_0028480 and TcBrA4_0088260; **5** (Tc5) = fusion of TcYC6_0100010 and TcBrA4_0074300; **6** (Tc6) = fusion of TcYC6_0043560 and TcYC6_0122760; **7** (Tc7) = fusion of TcYC6_0083710 and TcBrA4_0130080; **8** (Tc8) = TcYC6_0037170; **9** (Tc11) = TcYC6_0124160; **10** (Tc17) = fusion of TcBrA4_0028230 and TcBrA4_0029760; **11** (Tc19) = TcBrA4_0122270 and TcBrA4_0131050; **12** (tc2-tol2) = TcBrA4_0101960; **13** (3tolt) = portions of TcBrA4_0101970, TcYC6_0077100 and TcYC6_0078140; **14** (beta-tubulin) = TcYC6_0010960; **15** (G10) = TcCLB.504199.20; **16** (Kn107) = TcCLB.508355.250; **17** (LE2) = TcCLB.507447.19; Parvo = Recombinant Canine Parvovirus VP2 (MyBioSource.com).

Cardiac troponin

Cardiac troponin (cTnI) analysis was performed using the ADVIA Centaur CP immunoassay (Ultra-TnI, Siemens Medical Solutions USA, Inc., Malvern, PA) validated in dogs and with a reported range of 0.006 to 50.0 ng/mL [25].

Statistical analysis

The non-parametric Mann-Whitney U and unpaired t tests of the GraphPad Prism version 9.4 software were used for the analysis of the mouse experimental data. Values are expressed as means ± standard error of mean. Statistical evaluation of new infections in dogs over the prophylaxis period was determined by the Gehan-Breslow-Wilcoxon test (GraphPad Prism).

Results

We had previously shown that weekly [15] or twice weekly administration of high dose (2.5–5 X the normal daily dose) BNZ could cure established infections with *T. cruzi* in mice. To

determine if BNZ might also prevent the initial establishment of *T. cruzi* in naïve mice, we conducted a pilot study (Fig 1A) using twice weekly delivery of low dose BNZ (100 mg/kg oral, the standard daily dosage for continuous treatment in mice [26]). At 3.5 weeks (between the 5th and 6th BNZ dose) all mice were injected i.p. with 1000 trypomastigotes of the luciferase transgenic Colombiana strain of *T. cruzi*. Groups of both wild-type (C57BL/6J) and IFNγ deficient mice were included in the study; the IFNγ deficient (KO) mice are highly susceptible to *T. cruzi* infection [15,27] and were expected to reveal even very low levels of persistent infection. Untreated mice in both groups exhibited evidence of active infection at 14 days post-exposure and beyond and as expected, all mice in the IFNγ deficient group not receiving prophylaxis experienced uncontrolled infections and had to be euthanized by ~21 days post-exposure. In contrast, some BNZ-prophylaxed IFN-g KO mice showed low level luciferase signal at day 14 post-exposure but not at 12 weeks, and none of the mice in the BNZ-treated WT group had a detectable luciferase signal above background throughout the study (Fig 1B and 1C and S1 Fig).

Infection exposure was also confirmed in mice by monitoring the generation of *T. cruzi* -induced CD8[+] T cells specific for the immunodominant TSKb20 epitope [26]. With the exception of one prophylaxed IFNγ KO mouse, all mice exhibited *T. cruzi* -specific CD8[+] T cell responses with comparable numbers in the untreated WT and prophylaxed IFNγ KO mice and lower levels in the prophylaxed WT mice. We have previously shown that the expression of the T cell central memory marker CD127 on these parasite-specific T cells is a useful surrogate for parasite load (pathogen-specific central memory CD8+ T cells increase CD127 expression in the absence of continuing antigen stimulation; [15,26]) and the 2 groups under prophylaxis had a substantially higher fraction of CD127[+] cells in the TSKb20-specific population relative to mice not receiving prophylaxis, consistent with the expected low/absent parasite burden through the 21st week of prophylaxis (Fig 1D).

Twice weekly BNZ was continued for a total of 24 weeks, simulating a seasonal period of vector activity typical of south Texas [13]. In WT mice with or without prophylaxis, infection was not readily detectable by whole animal imaging through the prophylaxis period. However, in the IFNγ KO mice, although the infection was largely controlled by the prophylaxis treatment, the systemic infection was barely detectable during the prophylactic treatment period (S1 Fig) and within 4 weeks of termination of BNZ prophylaxis, 4 of 5 mice in the previously treated IFNγ KO mice group were systemically parasite-positive and had to be euthanized (Fig 1C and S1 Fig). The remaining animals in all groups were euthanized at week 33 of the study and skeletal muscle and cardiac tissues were examined for the presence of *T. cruzi* using qPCR. As shown in Fig 1E, all of the untreated WT mice were PCR positive for *T. cruzi* DNA in one or more of the samples from skeletal muscle, heart, or gut. In contrast, at least 3 of the 5 WT mice receiving BZN prophylaxis and the surviving IFNγ KO mouse were negative for *T. cruzi* DNA (the remaining 2 WT-treated mice were at or below the level of detection in this assay in skeletal muscle only). Collectively, these results suggest that the prophylaxis regimen employed here in WT mice prevented or truncated an infection in most cases. However, the protective effect of prophylaxis generally required a coincident intact immune response, as most IFNγ deficient mice became and remained infected despite prophylaxis.

Building upon these encouraging results in mice, we next asked if BNZ prophylaxis could reduce infection in kennel and hunting dog populations in the south-central U.S. where infection pressure was high, despite other vector control efforts [11]. We conducted an early spring (March to April) screening to identify uninfected dogs in this setting with the intent of capturing infection status prior to the window of high vector activity [13], using a combination of negative serological tests and negative blood PCR (Fig 2A). The rationale for using this combination of tests is that although blood PCR can provide solid evidence of active infection, a

Fig 2. Initial screening results with multiplex serology and PCR to identify *T. cruzi*-negative dogs to enroll in the prophylaxis study. (A) Schematic representation of dog screening and prophylaxis trial. Heatmaps of antibody levels (mean fluorescence intensity; MFI) and qPCR measurement of *T. cruzi* DNA in blood were used to classify dogs as uninfected **(B)**, *T. cruzi*-infected **(C)**, or seronegative but with a blood PCR result that did not reach the cut-off for being considered positive **(D)**. Recombinant *T. cruzi* proteins are defined in the Materials and Methods; lysate = a sonicate of *T. cruzi* trypomastigotes and amastigotes; GFP = recombinant green fluorescent protein (negative antigen control); Parvo = Parvovirus vaccine antigen (positive serological control).

https://doi.org/10.1371/journal.pntd.0010688.g002

negative blood PCR assay is not a dependable indicator of absence of infection. Additionally, serologic tests may not detect very recent infections. A total of 126 dogs of previously undetermined infection status were screened using a Luminex-based assay previously employed for detection and monitoring *T. cruzi* infection in humans [28–30] and other species [24,31], a commercial Stat-Pak test (ChemBio, NY) that is validated for humans but commonly used for research purposes in dogs [32,33], and by blood PCR. Fig 2B displays dogs considered to be infection-negative based upon the Luminex assay and confirmed in most cases by Stat-Pak and indirect fluorescent antibody (IFA) (Texas A&M Veterinary Medical Diagnostic Laboratory, College Station, TX; [32]) assays (S1 Table; n = 59; 46.8% of total screened). Nearly all dogs had detectable antibodies to the parvovirus vaccine antigen, confirming the quality of the serum sample, and in all cases the negative *T. cruzi* serology was supported by a negative blood PCR assay.

Fig 2C shows the antibody and/or PCR+ dogs that were excluded from the prophylaxis trial by virtue of having prior exposure and likely active infection (n = 53; 42.1% of those screened). Roughly half (29/53; 54.7%) of the dogs with detectable (generally robust) serological responses also had *T. cruzi* DNA in their blood as determined by qPCR. It is notable that, as in other species [24,28–31], the pattern of antigen specificity of antibody responses in these subjects varied extensively, although the antigen in lane 8, a polyubiquitin protein, appeared to be the most

Fig 3. Multiplex serological and blood PCR changes over the transmission season in dogs receiving or not BNZ prophylaxis. (A) Serological and PCR negative dogs (see Fig 2) were randomly assigned to the untreated or BNZ treatment groups and then rescreened at ~12 and ~24 weeks after the beginning of prophylaxis. One dog in each group (gray fill) was moved to BNZ treatment protocol after the 12 week sampling point due to high serum cardiac troponin I (cTnI) levels. One dog in each group was lost to follow-up before the 24 week sampling time due to death or sold by owner. Antigens used in the multiplex assay are as described in Fig 2 and the Materials and Methods. Blood PCR was considered positive if below the cut-off Ct value of 35. **(B)** Fraction of uninfected dogs in the initial screening group and their decrease in frequency as assessed in **(A)** at the midpoint (12 weeks) and end of treatment (24 weeks) sample timepoints (top) and comparison of the percentage of uninfected dogs in the untreated and prophylaxed groups over the study period (bottom).

https://doi.org/10.1371/journal.pntd.0010688.g003

reliable. A fraction of the screened dogs (n = 14; 11.1%) were seronegative by Luminex and other assays but had a weak signal in the blood PCR assay that was measurable, but above our standard cutoff for determining infection (Ct < 35.0; Fig 2D and S1 Table). These dogs were initially enrolled in the prophylaxis study as uninfected but 4 of these may have already been infected and these were excluded from prophylaxis study analysis (detailed further below).

The 67 animals considered infection-negative and available for enrollment were randomly assigned to either a control (no therapy) or a prophylactic group, which received twice weekly doses of BNZ at a level of not less than 10 mg/kg. This dosage is approximately the normal **daily** dose previously used (mostly ineffectively) to attempt drug-cure in dogs [34–36]. Dogs in these groups were then re-sampled 10–12 weeks (considered the midpoint of the transmission season) and ~24 weeks (end of season).

Apparently new infections occurred in both the control (n = 6; 18.2%) and prophylaxis (n = 9; 26.5%) groups, yielding a combined seasonal infection incidence of 22.4%. In all but one case, these infections occurred early in the season, prior to the 12 week screening timepoint (Fig 3). One newly-infected dog in each group was lost to follow up before the 24 week sampling point (one was sold and one died due to *T. cruzi* with severe, acute, lymphohistiocytic, necrotizing pancarditis with intralesional amastigotes). Additionally, one infected dog in each group was removed from the study after the mid-point sampling due to high serum cardiac troponin I (cTnI) levels (indicative of active heart damage) and started on a treatment

protocol consisting of higher dose BNZ (to be reported on elsewhere). Thus, BNZ prophylaxis as employed in this study had no impact on the number of new infections in this high intensity transmission setting (Fig 3B inset).

The serial sampling during a transmission season and the stable pattern of the antibody profiles in infected subjects provided the opportunity for several additional novel observations. First, 4 of the 14 seronegative dogs with blood PCR signals exceeding the positive cutoff point (Fig 2C) developed a seropositive profile during follow-up (Fig 4) and 3 of the 4 developed strong blood PCR signals. While these could represent new infections acquired during the follow-up period, they may also indicate dogs that were already infected at the time of the March/April survey but were so early in the infection course that antibody responses had not developed and parasites in the blood were low. The remaining 12 dogs in this subset were equally dispersed in the untreated and prophylaxis groups and none developed evidence of infection during the 24-week follow-up (Fig 3 and S1 Table). Looking retrospectively, one dog in each group in the prophylaxis trial was PCR negative (JRHE2, prophylaxis group and PAST16, control group) but was nonetheless also likely already infected at the pre-season survey point, as both had low reactivity to several *T. cruzi* antigens in the multiplex assay at this point but with a pattern that matched the more robust antigen recognition pattern in the Luminex assay that ultimately developed by the 12 and 24 week sampling points (Fig 3).

Lastly, one dog in the control group (LOST13, Fig 3A) had developed a substantial antibody profile by the 12 week sampling point (at which he was also PCR positive), but had essentially totally lost this response by the 24 week screening point. This dog was also strongly positive by a StatPak antibody test and had detectable serum cTnI (0.021 ng/mL) at 12 weeks but was seronegative and had cTnI below lower detection limit of 0.006 ng/mL at the 24 week sample time point. The continued detection of parvovirus-specific antibodies over this same time course ruled out concerns on sample quality or immune competency. A similar pattern of cure was evident in dog BEHE4 (Fig 4) after he was switched to a BNZ treatment regimen (increasing the dosage to 30 mg/kg twice a week) due to high cTnI levels in the 12 week sample. This dog became PCR negative and seronegative by the 24 week sample point. Collectively, these data

Fig 4. Multiplex serological and blood PCR changes over the transmission season in dogs that were seronegative but PCR undetermined in the pre-transmission season screening (see Fig 2). Antigens used in the multiplex assay are as described in Fig 2 and the Materials and Methods. * moved to a high dose BNZ treatment protocol after 12 week sample point.

support a potential early infection spontaneous cure in one dog and BNZ-induced cure in another, both resulting in a rapid decline in serological evidence of the previous infection.

Discussion

Our previous studies have extensively documented the high risk of *T. cruzi* infection in dogs in south central Texas, including among kenneled working dog populations [11,21,32]. New infection rates of up to 30%/year put these valuable animals at high risk for morbidity and early death. It is noteworthy that this high incidence of infection is occurring despite vector awareness education for dog owners and the implementation of a variety of vector control measures. Likely, the abundance of insect vectors and wildlife reservoirs with active *T. cruzi* infections, the outdoor group housing conditions that expose dogs to this infection risk, and the propensity of dogs to ingest these vectors and their feces, all combine to promote this high transmission situation. The lack of interventions such as vaccines that could reduce the incidence of new infections and the high failure rates of potential therapies leave few options for reducing the impact of *T. cruzi* in these settings.

In this study, we explored the potential of BNZ, a drug that has been in use for >50 years for the treatment of *T. cruzi* infection, in a prophylactic modality to attempt to reduce the rate of new infections in dogs. To our knowledge, prophylactic use of trypanocidal drugs has not been previously explored for prevention of new infections with *T. cruzi* [37], although prophylaxis has occasionally been employed to prevent potential exacerbation of infection due to immunosuppression following tissue transplantation in humans [38]. The premise behind these studies was that dosing BNZ at a standard daily dose level, but administering it twice per week instead of daily, could prevent establishment of new infections, or might rapidly terminate those infections before they could become firmly established. The twice-weekly dosing pattern is supported by the ability of BNZ to cure established *T. cruzi* infections in mice using this schedule, albeit with 2.5-5-fold the dose level used here for prophylaxis. Selection of this lower prophylactic dose, bi-weekly schedule was also driven by the practicality in terms of time/effort, cost, and cumulative drug toxicity over a potential 6-month transmission season. Given that trypanocidal activity of nitroimidazoles is likely maximum concentration driven, rather than via maintaining a constant minimal concentration [39], the logic of this approach was that intermittent drug exposure would not prevent infection in all cases, but might eliminate parasites within days after exposure and before the infection could become firmly established.

Trials of BNZ-based prophylaxis in laboratory mice validated this approach, demonstrating a substantial reduction in parasite burden and the ultimate resolution of infection in the majority of immunocompetent mice under the intermittent, low level BZN dosing protocol. Notably, this protocol had much less impact in mice compromised in the ability to produce IFNγ, an essential component of the anti-*T. cruzi* immune response. This latter result supports the hypothesis that a competent immune response likely works in concert with trypanocidal drugs to ultimately clear *T. cruzi* infection when treatment is successful.

However, in dogs in a high transmission setting, prophylaxis as applied here failed to prevent new infections during a 6-month transmission season. A number of factors could have contributed to this differential result in mice and dogs, primary among them, the likely differential parasite exposure. Mice received a single sub-lethal intraperitoneal injection of 1000 trypomastigotes, while dogs were potentially exposed repeatedly to infection, possibly at much higher doses, and likely via an oral route. The fact that one dog newly infected during the study period died and others exhibited high serum cTnI levels, prompting their transfer to a higher treatment dose regimen, supports the higher (and also variable) exposure conditions

for dogs in this study. Effective prophylaxis under these scenarios might require a more aggressive dosing regimen, either more frequent or with higher dosage or both.

Although not designed to explicitly address this point, the infection pattern observed in this study supports a seasonality in infection potential. We estimated the transmission season based upon cumulative vector sighting observations collected by our Kissing Bug Community Science initiative [13], which suggested vector activity beginning in May and peaking in July. However, at least 4 dogs were borderline PCR positive but seronegative in early May, and all developed serological responses, 3 of the 4 within 10–12 weeks of the initial sampling. Additionally, two dogs that were PCR-negative, but had a suggestion of a serological response at initial screening, were PCR positive 10–12 weeks later. Collectively, these data indicate that new infections may be occurring before our early May prophylactic dosing. In combination with the fact that most new infections occurred in the first 12 weeks dosing period, it seems likely that beginning prophylaxis earlier in the year could have had a greater impact in the rate of new infections. Including these four "pre-prophylaxis" infected dogs as among those infected in 2021 year increases the yearly incidence in this setting to 26.8% (19/71).

To our knowledge, no previous study has sampled a susceptible, at risk, animal population at the frequency and with both PCR and multiple serology as employed in this study. In addition to the high infection pressure, this setting is also optimal for collection of novel and valuable data because new dogs are introduced each season, through either breeding or new acquisitions. Among the interesting observations from this first screening year is that 14 of the 15 (or 18 of 19 if the 4 pre-May infections are included) new infections occurred before the calculated mid-point of the estimated transmission season. The reason for this early season bias is not known, but could be due to opportunity based on location, or to behavior (e.g. aggressive bug eaters are more likely to be exposed and become infected) or a combination of the two. Given the high early season incidence, it is clear that the opportunities for infection are high even when bug activity appears low. Identifying the specific links between bug numbers, locations and infection status with the seasonality of new infections in dogs should be addressed in future seasonal studies. Active entomological surveillance at sentinel locations within the geographic region of study would be useful to establish a more precise start of the seasonal insect activity period, so that prophylaxis in future years could be initiated prior to insect activity.

The frequency of sampling applied herein also allowed for the detection of one apparent case of spontaneous cure of an acute infection. Although such spontaneous cures have been anecdotally reported in chronically infected hosts, both animal [40] and human [41], to our knowledge cure during the acute infection has not been documented. The frequency of such cures is worth exploring further and as well, the protection from re-infection that might be afforded by such cases. The very rapid waning of the antibody response in this case, as well as following an apparent BNZ treatment dose-induced cure, was also surprising and would have gone undetected if screening was conducted only once or twice per year, for example.

The use of both a multiplex serological test and blood PCR to track new infections was critical to the technical success of this project and for revealing some of the less expected observations. The frequent failure of PCR to detect many chronic infections with *T. cruzi* is well recognized [31]. The multiple antigen array used in this study, incorporating >25 parasite proteins, a crude lysate, and both positive and negative control proteins, provides a confidence in detection of infection that is lacking in single antigen or whole parasite assays. However, all serological assays fail infection detection very early, before anti-parasite antibodies have been formed. Thus, the combined use of PCR and multiplex serology provided insights that would have been missed using either approach alone.

Also, not addressed in this study is whether prophylaxis, while not reducing the incidence of infection, might be beneficial by ultimately reducing the severity of disease. Anecdotally we

observed that several dogs infected while under prophylaxis nonetheless experienced high serum levels of cTnI, indicating that prophylaxis in these cases was not preventing acute phase disease. A longer-term follow-up of disease development with and without early prophylaxis might be revealing. However, ideally, when infection is detected in these working dogs, they should be enrolled in an effective treatment regimen (as done for dogs BEHE4 and CHHE1) that enhances the chances of resolving the infection and thus preventing disease progression.

Although the seasonal monitoring for new infections in a population at high risk of infection provided new insights into *T. cruzi* transmission and development of immune responses, the prophylaxis approach applied here did not prevent infection in this setting. Future studies might apply prophylaxis earlier in the transmission season or at a more aggressive dosing level. Also, it would be of interest to determine if prophylaxis, while failing to reduce infection incidence, might be beneficial with respect to reducing infection impact either in the short-term, or long-term.

Supporting information

S1 Fig. Images of *T. cruzi* bioluminescent signal in mice (ventral view) at various times post study initiation (see Fig 1A) Note: Only 3 of the 5 mice in WT groups were imaged at 24 weeks.
(PDF)

S1 Table. Pre-study dog survey data.
(XLSX)

Acknowledgments

Author Contributions

Conceptualization: Juan M. Bustamante, Angel M. Padilla, Ashley B. Saunders, Sarah A. Hamer, Rick L. Tarleton.

Data curation: Juan M. Bustamante, Lisa D. Auckland, Rachel E. Busselman, Stephanie Collins, Elizabeth L. Malcolm, Briana F. Wilson.

Formal analysis: Juan M. Bustamante, Angel M. Padilla, Rick L. Tarleton.

Funding acquisition: Ashley B. Saunders, Sarah A. Hamer, Rick L. Tarleton.

Investigation: Angel M. Padilla, Brooke White, Rick L. Tarleton.

Methodology: Brooke White, Lisa D. Auckland, Rick L. Tarleton.

Project administration: Stephanie Collins, Ashley B. Saunders, Sarah A. Hamer, Rick L. Tarleton.

Resources: Stephanie Collins.

Supervision: Ashley B. Saunders, Sarah A. Hamer, Rick L. Tarleton.

Writing – original draft: Juan M. Bustamante, Ashley B. Saunders, Sarah A. Hamer, Rick L. Tarleton.

Writing – review & editing: Angel M. Padilla, Lisa D. Auckland, Rachel E. Busselman, Stephanie Collins, Elizabeth L. Malcolm, Briana F. Wilson, Ashley B. Saunders, Sarah A. Hamer, Rick L. Tarleton.

References

1. Bern C, Kjos S, Yabsley MJ, Montgomery SP. Trypanosoma cruzi and Chagas' Disease in the United States. Clin Microbiol Rev. 2011; 24(4):655–81. Epub 2011/10/07. https://doi.org/10.1128/CMR.00005-11 PMID: 21976603.

2. Roellig DM, Ellis AE, Yabsley MJ. Oral transmission of Trypanosoma cruzi with opposing evidence for the theory of carnivory. The Journal of parasitology. 2009; 95(2):360–4. Epub 2008/09/04. https://doi.org/10.1645/GE-1740.1 PMID: 18763853.

3. Barr SC. Canine Chagas' disease (American trypanosomiasis) in North America. Vet Clin North Am Small Anim Pract. 2009; 39(6):1055–64, v–vi. Epub 2009/11/26. https://doi.org/10.1016/j.cvsm.2009.06.004 PMID: 19932362.

4. Velasquez-Ortiz N, Ramirez JD. Understanding the oral transmission of Trypanosoma cruzi as a veterinary and medical foodborne zoonosis. Res Vet Sci. 2020; 132:448–61. Epub 2020/08/12. https://doi.org/10.1016/j.rvsc.2020.07.024 PMID: 32781335.

5. Montenegro V, Jimenez M, Pinto Dias J, Zweledon R. Chagas Disease in dogs from endemic areas of Costa Rica. Memorias do Instituto Oswaldo Cruz. 2002; 97:491–4. https://doi.org/10.1590/s0074-02762002000400006 PMID: 12118277

6. Gurtler RE, Cardinal MV. Reservoir host competence and the role of domestic and commensal hosts in the transmission of Trypanosoma cruzi. Acta tropica. 2015; 151:32–50. https://doi.org/10.1016/j.actatropica.2015.05.029 PMID: 26051910.

7. Estrada-Franco JG, Bhatia V, Diaz-Albiter H, Ochoa-Garcia L, Barbabosa A, Vazquez-Chagoyan JC, et al. Human Trypanosoma cruzi infection and seropositivity in dogs, Mexico. Emerging infectious diseases. 2006; 12(4):624–30. Epub 2006/05/18. https://doi.org/10.3201/eid1204.050450 PMID: 16704811.

8. Jaimes-Duenez J, Triana-Chavez O, Cantillo-Barraza O, Hernandez C, Ramirez JD, Gongora-Orjuela A. Molecular and serological detection of Trypanosoma cruzi in dogs (Canis lupus familiaris) suggests potential transmission risk in areas of recent acute Chagas disease outbreaks in Colombia. Prev Vet Med. 2017; 141:1–6. Epub 2017/05/24. https://doi.org/10.1016/j.prevetmed.2017.03.009 PMID: 28532988.

9. Busselman RE, Hamer SA. Chagas Disease Ecology in the United States: Recent Advances in Understanding Trypanosoma cruzi Transmission Among Triatomines, Wildlife, and Domestic Animals and a Quantitative Synthesis of Vector-Host Interactions. Annu Rev Anim Biosci. 2022; 10:325–48. Epub 2021/11/11. https://doi.org/10.1146/annurev-animal-013120-043949 PMID: 34758274.

10. Meyers AC, Edwards EE, Sanders JP, Saunders AB, Hamer SA. Fatal Chagas myocarditis in government working dogs in the southern United States: Cross-reactivity and differential diagnoses in five cases across six months. Vet Parasitol Reg Stud Reports. 2021; 24:100545. Epub 2021/05/25. https://doi.org/10.1016/j.vprsr.2021.100545 PMID: 34024363.

11. Busselman RE, Meyers AC, Zecca IB, Auckland LD, Castro AH, Dowd RE, et al. High incidence of Trypanosoma cruzi infections in dogs directly detected through longitudinal tracking at 10 multi-dog kennels, Texas, USA. PLoS neglected tropical diseases. 2021; 15(11):e0009935. Epub 2021/11/11. https://doi.org/10.1371/journal.pntd.0009935 PMID: 34758049.

12. Madigan R, Majoy S, Ritter K, Luis Concepcion J, Marquez ME, Silva SC, et al. Investigation of a combination of amiodarone and itraconazole for treatment of American trypanosomiasis (Chagas disease) in dogs. Journal of the American Veterinary Medical Association. 2019; 255(3):317–29. Epub 2019/07/13. https://doi.org/10.2460/javma.255.3.317 PMID: 31298647.

13. Curtis-Robles R, Wozniak EJ, Auckland LD, Hamer GL, Hamer SA. Combining Public Health Education and Disease Ecology Research: Using Citizen Science to Assess Chagas Disease Entomological Risk in Texas. PLoS neglected tropical diseases. 2015; 9(12):e0004235. Epub 2015/12/15. https://doi.org/10.1371/journal.pntd.0004235 PMID: 26658425.

14. Sanchez-Valdez FJ, Padilla A, Wang W, Orr D, Tarleton RL. Spontaneous dormancy protects Trypanosoma cruzi during extended drug exposure. eLife. 2018; 7. https://doi.org/10.7554/eLife.34039 PMID: 29578409.

15. Bustamante JM, Sanchez-Valdez F, Padilla AM, White B, Wang W, Tarleton RL. A modified drug regimen clears active and dormant trypanosomes in mouse models of Chagas disease. Sci Transl Med. 2020; 12(567). Epub 2020/10/30. https://doi.org/10.1126/scitranslmed.abb7656 PMID: 33115952.

16. Canavaci AM, Bustamante JM, Padilla AM, Perez Brandan CM, Simpson LJ, Xu D, et al. In vitro and in vivo high-throughput assays for the testing of anti-Trypanosoma cruzi compounds. PLoS neglected tropical diseases. 2010; 4(7):e740. Epub 2010/07/21. https://doi.org/10.1371/journal.pntd.0000740 PMID: 20644616.

17. Bustamante JM, Craft JM, Crowe BD, Ketchie SA, Tarleton RL. New, combined, and reduced dosing treatment protocols cure Trypanosoma cruzi infection in mice. The Journal of infectious diseases. 2014; 209(1):150–62. Epub 2013/08/16. https://doi.org/10.1093/infdis/jit420 PMID: 23945371.

18. Cummings KL, Tarleton RL. Rapid quantitation of Trypanosoma cruzi in host tissue by real-time PCR. Molecular and biochemical parasitology. 2003; 129(1):53–9. https://doi.org/10.1016/s0166-6851(03)00093-8 PMID: 12798506.

19. Piron M, Fisa R, Casamitjana N, Lopez-Chejade P, Puig L, Verges M, et al. Development of a real-time PCR assay for Trypanosoma cruzi detection in blood samples. Acta tropica. 2007; 103(3):195–200. https://doi.org/10.1016/j.actatropica.2007.05.019 PMID: 17662227.

20. Duffy T, Cura CI, Ramirez JC, Abate T, Cayo NM, Parrado R, et al. Analytical performance of a multiplex Real-Time PCR assay using TaqMan probes for quantification of Trypanosoma cruzi satellite DNA in blood samples. PLoS neglected tropical diseases. 2013; 7(1):e2000. Epub 2013/01/26. https://doi.org/10.1371/journal.pntd.0002000 PMID: 23350002.

21. Meyers AC, Meinders M, Hamer SA. Widespread Trypanosoma cruzi infection in government working dogs along the Texas-Mexico border: Discordant serology, parasite genotyping and associated vectors. PLoS neglected tropical diseases. 2017; 11(8):e0005819. Epub 2017/08/09. https://doi.org/10.1371/journal.pntd.0005819 PMID: 28787451.

22. Curtis-Robles R, Auckland LD, Hodo CL, Snowden KF, Nabity MB, Hamer SA. Trypanosoma cruzi discrete typing unit TcIV implicated in a case of acute disseminated canine Chagas disease. Vet Parasitol Reg Stud Reports. 2018; 12:85–8. Epub 2019/04/25. https://doi.org/10.1016/j.vprsr.2018.02.006 PMID: 31014814.

23. Cooley G, Etheridge RD, Boehlke C, Bundy B, Weatherly DB, Minning T, et al. High Throughput Selection of Effective Serodiagnostics for Trypanosoma cruzi infection. PLoS neglected tropical diseases. 2008; 2(10):e316. https://doi.org/10.1371/journal.pntd.0000316 PMID: 18841200.

24. Hartley AN, Cooley G, Gwyn S, Orozco MM, Tarleton RL. Frequency of IFNgamma-producing T cells correlates with seroreactivity and activated T cells during canine Trypanosoma cruzi infection. Vet Res. 2014; 45:6. https://doi.org/10.1186/1297-9716-45-6 PMID: 24456537.

25. Winter RL, Saunders AB, Gordon SG, Miller MW, Sykes KT, Suchodolski JS, et al. Analytical validation and clinical evaluation of a commercially available high-sensitivity immunoassay for the measurement of troponin I in humans for use in dogs. J Vet Cardiol. 2014; 16(2):81–9. Epub 2014/05/20. https://doi.org/10.1016/j.jvc.2014.03.002 PMID: 24834862.

26. Bustamante JM, Bixby LM, Tarleton RL. Drug-induced cure drives conversion to a stable and protective CD8+ T central memory response in chronic Chagas disease. Nature medicine. 2008; 14(5):542–50. https://doi.org/10.1038/nm1744 PMID: 18425131.

27. Marinho CR, Nunez-Apaza LN, Martins-Santos R, Bastos KR, Bombeiro AL, Bucci DZ, et al. IFN-gamma, but not nitric oxide or specific IgG, is essential for the in vivo control of low-virulence Sylvio X10/4 Trypanosoma cruzi parasites. Scand J Immunol. 2007; 66(2–3):297–308. Epub 2007/07/20. https://doi.org/10.1111/j.1365-3083.2007.01958.x PMID: 17635807.

28. Alvarez MG, Ramirez JC, Bertocchi G, Fernandez M, Hernandez Y, Lococo B, et al. New Scheme of Intermittent Benznidazole Administration in Patients Chronically Infected with Trypanosoma cruzi: Clinical, Parasitological, and Serological Assessment after Three Years of Follow-Up. Antimicrobial agents and chemotherapy. 2020; 64(9). Epub 2020/06/24. https://doi.org/10.1128/AAC.00439-20 PMID: 32571827.

29. Viotti R, Vigliano C, Alvarez MG, Lococo B, Petti M, Bertocchi G, et al. Impact of aetiological treatment on conventional and multiplex serology in chronic Chagas disease. PLoS neglected tropical diseases. 2011; 5(9):e1314. https://doi.org/10.1371/journal.pntd.0001314 PMID: 21909451.

30. Laucella SA, Mazliah DP, Bertocchi G, Alvarez MG, Cooley G, Viotti R, et al. Changes in Trypanosoma cruzi-specific immune responses after treatment: surrogate markers of treatment efficacy. Clinical infectious diseases: an official publication of the Infectious Diseases Society of America. 2009; 49(11):1675–84. https://doi.org/10.1086/648072 PMID: 19877967.

31. Padilla AM, Yao PY, Landry TJ, Cooley GM, Mahaney SM, Ribeiro I, et al. High variation in immune responses and parasite phenotypes in naturally acquired Trypanosoma cruzi infection in a captive non-

human primate breeding colony in Texas, USA. PLoS neglected tropical diseases. 2021; 15(3): e0009141. Epub 2021/04/01. https://doi.org/10.1371/journal.pntd.0009141 PMID: 33788859.

32. Curtis-Robles R, Snowden KF, Dominguez B, Dinges L, Rodgers S, Mays G, et al. Epidemiology and Molecular Typing of Trypanosoma cruzi in Naturally-Infected Hound Dogs and Associated Triatomine Vectors in Texas, USA. PLoS neglected tropical diseases. 2017; 11(1):e0005298. https://doi.org/10.1371/journal.pntd.0005298 PMID: 28095511.

33. Nieto PD, Boughton R, Dorn PL, Steurer F, Raychaudhuri S, Esfandiari J, et al. Comparison of two immunochromatographic assays and the indirect immunofluorescence antibody test for diagnosis of Trypanosoma cruzi infection in dogs in south central Louisiana. Veterinary parasitology. 2009; 165(3–4):241–7. Epub 2009/08/04. https://doi.org/10.1016/j.vetpar.2009.07.010 PMID: 19647943.

34. Guedes PM, Veloso VM, Tafuri WL, Galvao LM, Carneiro CM, Lana M, et al. The dog as model for chemotherapy of the Chagas' disease. Acta tropica. 2002; 84(1):9–17. Epub 2002/10/22. https://doi.org/10.1016/s0001-706x(02)00139-0 PMID: 12387906.

35. Santos FM, Lima WG, Gravel AS, Martins TA, Talvani A, Torres RM, et al. Cardiomyopathy prognosis after benznidazole treatment in chronic canine Chagas' disease. The Journal of antimicrobial chemotherapy. 2012; 67(8):1987–95. https://doi.org/10.1093/jac/dks135 PMID: 22570424.

36. Cunha ELA, Torchelsen F, Cunha LM, de Oliveira MT, Fonseca KDS, Vieira PMA, et al. Benznidazole, itraconazole and their combination in the treatment of acute experimental chagas disease in dogs. Experimental parasitology. 2019; 204:107711. Epub 2019/06/30. https://doi.org/10.1016/j.exppara.2019.05.005 PMID: 31254494.

37. Van Voorhis WC. Therapy and prophylaxis of systemic protozoan infections. Drugs. 1990; 40(2):176–202. Epub 1990/08/01. https://doi.org/10.2165/00003495-199040020-00002 PMID: 2121456.

38. Rossi Neto JM, Finger MA, dos Santos CC. Benznidazole as Prophylaxis for Chagas Disease Infection Reactivation in Heart Transplant Patients: A Case Series in Brazil. Tropical Medicine and Infectious Disease. 2020; 5(3):132. https://doi.org/10.3390/tropicalmed5030132 PMID: 32824760

39. Meyer KJ, Meyers DJ, Shapiro TA. Optimal kinetic exposures for classic and candidate antitrypanosomals. The Journal of antimicrobial chemotherapy. 2019; 74(8):2303–10. Epub 2019/05/17. https://doi.org/10.1093/jac/dkz160 PMID: 31093674.

40. Tarleton RL. The role of immunology in combating *Trypanosoma cruzi* infection and Chagas disease. Revista Española de Salud Pública. 2013; 87:33–9.

41. Pinto Dias JC, Dias Emmanuel, Filho Olindo M., Vitelli-Avelar Danielle, Correia Dalmo, Lages Eliane et al. Further evidence of spontaneous cure in human chagas disease. Revista da Sociedade Brasileira de Medicina Tropical 2008; 41(5):505–6. https://doi.org/10.1590/s0037-86822008000500014 PMID: 19009195